Anti-VEGF inhibitors and Renal Safety in Onco-Nephrology consortium - Urinary Protein/Creatinine ratio

Survey on clinical practice regarding cancer chemotherapy and renal disorders using electronic medical record data, and research on related factors and prognosis - VERSiON UP study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000042545

Enrollment

105

Registered

2020-11-25

Start date

2019-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with gastric or colorectal cancer whose urinary protein qualitative test was 2+ at least once during treatment with angiogenesis inhibitors

Exclusion criteria

Exclusion criteria: Patients not using angiogenesis inhibitors

Design outcomes

Primary

Measure	Time frame
Percentage of less than UPCR 2 in cases with 2+ urinary protein qualitative test	—

Countries

Japan

Contacts

Public Contactmichio nakamura

Sapporo City General Hospital Gastroenterology

michio.nakamura@icloud.com011-726-2211

Outcome results